Open Access

Hepatotoxicity and Drug/Chemical Interaction Toxicity of Nanoclay Particles in Mice

  • Katsuhiro Isoda1Email author,
  • Ryutaro Nagata1,
  • Tomoya Hasegawa1,
  • Yuichiro Taira1,
  • Ikuko Taira1,
  • Yoshimi Shimizu1,
  • Kazuo Isama1,
  • Tetsuji Nishimura1 and
  • Isao Ishida1
Nanoscale Research Letters201712:199

https://doi.org/10.1186/s11671-017-1956-5

Received: 28 October 2016

Accepted: 24 February 2017

Published: 16 March 2017

Abstract

Nanomaterials are relatively new and unconventional materials with many useful properties, but their effects on biological systems are poorly understood. Nanoclay is a general term for layered mineral silicate nanoparticles that are ideally suited for use in clay-based nanocomposites. The potential biological hazards of nanoclays have not been addressed, however. Therefore, we investigated the in vivo effects and drug interactions of nanoclays. In mice, administration of nanoclay particles via the tail vein led to acute liver injury. Co-administration of nanoclay and carbon tetrachloride, paraquat, or cisplatin resulted in both liver and kidney injury. Our findings thus indicate that nanoclay particles are potentially hepato- and nephrotoxic.

Keywords

Nanoclay particles Liver injury Carbon tetrachloride Paraquat Cisplatin

Background

Recent advances in technologies for reducing the size of materials have led to the development of innovative nanomaterials with many potential applications. Nanomaterials are frequently used in microelectronics, cosmetics, and sunscreens, and their potential use in drug-delivery systems is being investigated [13]. Compared with micromaterials, nanomaterials have various unique physicochemical qualities related to size, surface structure, solubility, and aggregation characteristics. Thus, the reduction in particle size from the micro- to nanoscale could be beneficial in many industrial and scientific applications.

Despite their potential benefits, nanomaterials can exhibit toxicities not associated with micromaterials, making it essential to understand the biological activity and potential toxicity of nanomaterials [4, 5]. Considerable recent research has focused on the human health effects of inhalation of nanomaterials, and a number of risks have been identified. For example, occupational exposure to quartz, mineral dust particles, and asbestos have been shown to induce inflammation, fibrosis, and cytotoxicity in the lungs [6, 7]. Animal studies have revealed that carbon nanotubes are potentially carcinogenic in the lungs [8]. Silica nanoparticles reportedly induce liver injury and can penetrate the blood-brain barrier and enter the brain [9, 10]. Due to differences in the chemical composition of many nanoparticles, their toxicity varies as well [11]. It is possible that chemicals that are otherwise generally nontoxic to humans can be rendered toxic if presented via nano-sized particles.

Due to their viscosity, clay soils are capable of retaining considerable amounts of water. Clays have been used since ancient times as raw materials for ceramics [12], and they are composed of layered silicate minerals such as Si-O4, Al-O, and Mg-O arranged in a planar octahedron configuration. The nanoclays used in this study, Si-O4 and Al-O, are montmorillonites that form a continuous sheet-like conformation. One side of the sheet-like plane (100 nm or less) of the clay mineral is nanoclay.

Clays are used in a wide variety of products, including paints, cosmetics, and pharmaceuticals [13]. Compared with clays, nanoclays exhibit a number of advantageous properties, including higher workability, mechanical strength, and heat resistance. As such, it is expected that applications for nanoclays in products will increase in the future [14, 15]. However, as clay minerals are generally considered safe to humans, there are no reports examining the potential toxicity of nanoclays. In this study, therefore, the potential toxicity of nanoclay particles was evaluated using acute toxicity testing and drug interaction analyses in mice.

Methods

Materials

Nanoclay particles were obtained from Sigma-Aldrich Co. (St. Louis, MO). The nanoclay particles were in the form of a powder having a layered particle size with one side of 1 nm. For injection, nanoclay particles were dispersed at a concentration of 20 mg/ml in medical water for injection (Fuso Pharmaceutical Industries, Ltd., Japan). The nanoclay particles suspended in the injection water were then stirred and sonicated for 10 min. Analysis of the size distribution of the particles, as determined using a Zetasizer (Sysmex Co., Kobe, Japan) (Fig. 1), revealed an average particle diameter of 57.8 ± 12.3 nm for peak 1 and an average particle diameter of 648.3 ± 232.2 nm for peak 2. In addition, the peak 1 volume was 43.6% and the peak 2 volume was 56.4% (Fig. 1). The suspensions were thoroughly dispersed by sonication before use and then diluted with water. An equal volume of suspension was injected for each treatment. Paraquat and cisplatin were dissolved in saline and stored at −20 °C until use. Carbon tetrachloride was dissolved in olive oil. All reagents used were of research grade. Medical water (Fuso Pharmaceutical Industries, Ltd., Japan), which was used as the solvent for nanoclay particles, was used as the vehicle control.
Fig. 1

Results of particle diameter measurement of nanoclay particles. The average nanoclay particle diameter of peak 1 was 57.8 ± 12.3 nm, and the average nanoclay particle diameter of peak 2 was 648.3 ± 232.2 nm

Animals

Eight-week-old BALB/c male mice were purchased from Funabashi Farm Co., Ltd. (Chiba, Japan). Animals were maintained in a controlled environment (temperature: 23 ± 1.5 °C; 12-h light/dark cycle) with free access to standard rodent chow and water. The mice were given 1 week to acclimate before the experiments were conducted. The experimental protocols conformed to the ethical guidelines of the Teikyo Heisei University Graduate School of Pharmaceutical Sciences, compiled from the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Sciences.

Biochemical Analyses

Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes that leak into the blood during hepatic injury and are important indicators of liver injury [16]. Blood urea nitrogen (BUN) is an index to be inspected when the kidneys are working normally, and increases in BUN values are a measure of deterioration of the kidney function [17]. Serum ALT, AST, and BUN were measured using commercially available kits (Wako Pure Chemical Industries) according to the manufacturer’s protocols. Briefly, collected serum (10 ml) was combined with 1 ml of color A reagent (including urease) and incubated at 37 °C for 15 min. Following the addition of 1 ml of color B reagent, the sample was incubated at 37 °C for 10 min. Absorbance was measured at a wavelength of 570 nm.

Histologic Analyses

At 24 h after dose administration, animals were sacrificed, and the livers were removed and fixed with 4% paraformaldehyde. Following processing and sectioning, thin tissue sections were stained with hematoxylin and eosin for histologic observation.

Statistical Analyses

Statistical analyses were performed with Microsoft Excel with the Statcel add-in (EMS Publication Co., Ltd., Saitama, Japan). All data are presented as means ± standard error of the means. The significance of differences between the control and experimental groups was assessed using the Dunnett’s test. A P value <0.05 was considered indicative of statistical significance.

Results and Discussion

We initially examined the dose dependence of the liver toxicity of nanoclay particles. Acute liver injury was observed at the maximum dose of 20 mg/kg of nanoclay particles (Fig. 2a, b). Hematoxylin and eosin staining of liver tissue indicated extensive injury in mice administered with 20 mg/kg of nanoclay particles (Fig. 2c, d).
Fig. 2

Dose dependence of nanoclay particle-induced liver injury. Serum levels of the liver enzymes alanine aminotransferase (ALT) (a) and aspartate aminotransferase (AST) (b) were determined using commercially available kits (see Biochemical analyses section) 24 h after intravenous administration of nanoclay particles at the indicated doses. Histologic analyses of tissues of nanoclay particle-treated mice. At 24 h after administration of vehicle (c) or nanoclay particles (d), tissues were collected, fixed with 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin. Data are presented as mean ± standard error of the mean (n = 4). Significant difference (*P < 0.05, **P < 0.01) compared with the vehicle-treated group

We next investigated whether there are interactions between chemicals and nanoclay particles. To prevent interactions between the test chemicals and nanoclay particles prior to administration and absorption, the chemicals were injected intraperitoneally, and the nanoclay particles were injected intravenously. Carbon tetrachloride is known to induce hepatic injury following intraperitoneal administration [18]. We therefore administered carbon tetrachloride to mice at a dose that does not induce hepatic injury (0.01 ml/kg). Treatment with both carbon tetrachloride and nanoclay particles caused significant toxicity, with most of the toxicity associated with the nanoclay particles. Co-administration of carbon tetrachloride and nanoclay particles (5 mg/kg) resulted in increases in serum ALT and AST levels (Fig. 3).
Fig. 3

Effect of co-administration of nanoclay particles on carbon tetrachloride-induced toxicity. Mice were injected intraperitoneally with carbon tetrachloride at 0.01 ml/kg together with intravenous injection of vehicle or nanoclay particles (5 mg/kg). At 24 h post-injection, serum levels of the liver enzymes alanine aminotransferase (ALT, open bars) and aspartate aminotransferase (AST, solid bars) were determined using commercially available kits (see Methods). Data are representative of three independent experiments and are presented as the mean ± standard error of the mean (n = 4). Significant difference (*P < 0.05) between vehicle- and carbon tetrachloride-treated groups

We also investigated the potential impact of interaction with paraquat on the toxicity of nanoclay particles. Paraquat is one of the most widely used and highly toxic herbicides. Co-administration of paraquat (50 mg/kg) and nanoclay particles (5 mg/kg) led to synergistic significant elevations in serum ALT, and AST levels compared with nanoclay particles and paraquat administered alone (Fig. 4a). Serum BUN levels were also significantly elevated following co-administration of nanoclay particles and paraquat (Fig. 4b). When nanoclay particles and paraquat were administered at the same time, ALT increased from 41.5 in the nanoclay particles alone group and from 48.3 in the paraquat alone group to 126.6. AST increased from 257.6 in the nanoclay particles alone group and 354.6 in the paraquat alone group to 634.1. By simultaneous administration of nanoclay and paraquat, the rise in ALT was synergistic and the rise in AST was additive. It is necessary to examine the mechanism of exacerbation of liver injury by co-administration of nanoclay particles and paraquat.
Fig. 4

Effect of nanoclay particles (NC) on paraquat (PQ)-induced toxicity. Mice were injected intraperitoneally with PQ at 50 mg/kg together with intravenous injection of vehicle or NC (5 mg/kg). a At 24-h post-injection, serum levels of the liver enzymes alanine aminotransferase (ALT, open bars) and aspartate aminotransferase (AST, solid bars) were determined using commercially available kits (see Methods). b Plasma levels of blood urea nitrogen (BUN). Data are representative of three independent experiments and are presented as mean ± standard error of the mean (n = 4). Significant difference (*P < 0.05, **P < 0.01) between vehicle- and PQ-treated groups

We also investigated the interaction between cisplatin and nanoclay particles. Administration of cisplatin causes a variety of adverse effects, such as renal and hepatic failure [19, 20]. Co-administration of cisplatin (80 μmol/kg) and nanoclay particles (5 mg/kg) produced a synergistic elevation in serum levels of ALT (from 16.3 [control] to 611.7 KU) and AST (from 50.4 [control] to 802.6 KU) (Fig. 5a). Serum BUN levels increased from 30.4 (control) to 90.5 mg/ml (Fig. 5b).
Fig. 5

Effect of nanoclay particles (NC) on cisplatin (CDDP)-induced toxicity. Mice were injected intraperitoneally with CDDP at 80 μmol/kg together with intravenous injection of vehicle or NC (5 mg/kg). a At 24-h post-injection, serum levels of the liver enzymes alanine aminotransferase (ALT, open bars) and aspartate aminotransferase (AST, solid bars) were determined using commercially available kits (see Methods). b Plasma levels of blood urea nitrogen (BUN). Data are representative of three independent experiments and are presented as the mean ± standard error of the mean (n = 4). Significant difference (**P < 0.01) between the vehicle- and CDDP-treated groups

We were able to induce acute liver injury by administering nanoclay particles via the tail vein in mice. Our study is also the first to report liver injury induced by co-administration of nanoclay particles and carbon tetrachloride, paraquat, or cisplatin and kidney injury induced by co-administration of nanoclay particles and paraquat or cisplatin.

Suspension of the montmorillonite nanoclay particles in an aqueous solution resulted in the formation of aggregates with an average particle diameter of 57.8 ± 12.3 nm and 648.3 ± 232.2 nm. However, approximately 46% of the dispersed nanoclay particles exhibited a particle size of ≤100 nm (Fig. 1). The particle size of the nanoclay suspension before sonication was 625 ± 147.6 nm (Additional file 1: Figure S1). Approximately 54% of nanoclay particles suspended by sonication exhibited a size of <100 nm. This result indicates that at least some of the nanoclay particles did not aggregate. We tried to develop a suspension method in which nanoclay particles of 100 nm would be uniformly dispersed, but these efforts were unsuccessful. In the future, it will be necessary to develop a suspension process that does not promote aggregation of the nanoclay particles.

Previously, we reported that hepatic injury was induced by combining silica nanoparticles and polystyrene nanoparticles with carbon tetrachloride or paraquat [9, 21]. We think that it is rare for a nanoclay particles and carbon tetrachloride or paraquat to be used together in real-world situations as they were in this experiment. However, it is possible that hepatic injury may occur by using a liver injury–inducing chemical substance and nanoclay particles in combination. Furthermore, it is necessary to consider combinations of various liver injury-inducing chemicals and nanoclay particles.

Acute liver injury was induced following administration of 10 or 20 mg/kg of nanoclay particles to mice via the caudal vein (Fig. 1). BUN levels, however, did not increase, and no kidney injury was observed (data not shown). In addition, hematoxylin-eosin staining of the lung tissue of mice treated with nanoclay particles provided evidence of lung injury (data not shown). These data suggest that administration of nanoclay particles causes liver injury. Previously, we reported that silica nanoparticles of 70 nm diameter accumulate in the liver, leading to acute liver injury [22]. Yoshida et al. reported that silica nanoparticles are distributed to both the liver and the brain [23]. In addition, Yu et al. reported that silica nanoparticles accumulate in the liver and spleen in mice [24]. Based on these reports, it is reasonable to conclude that the accumulation of nanoclay particles in the liver would also induce liver injury in mice. Future studies should focus on the correlation between liver injury and the amount of nanoclay particles that accumulate in that organ.

We also investigated the combined effects of various chemicals on nanoclay particle-induced toxicity and found that carbon tetrachloride, cisplatin, and paraquat exhibit synergistic toxic effects with nanoclay particles. Liver injury induced by carbon tetrachloride, paraquat, or cisplatin is caused by oxidative stress [25, 26]. Micro- or nano-sized clays also reportedly induce the production of reactive oxygen species (ROS) in vivo [27]. Increased production of ROS following co-administration of nanoclay particles and chemicals is also consistent with liver injury following co-administration. We will perform further biochemical and comprehensive analyses, such as proteomic and genomic studies, to elucidate the mechanism of these synergistic effects.

Conclusions

In summary, we demonstrated that nanoclay particles can cause liver damage and that this effect can be synergistically exacerbated as a result of interactions with hepatotoxic chemicals or drugs. Further studies based on these data will be required to fully elucidate the toxicologic profiles of nanoparticles proposed for use in human medicine.

Abbreviations

ALT: 

Alanine aminotransferase, AST: aspartate aminotransferase

BUN: 

Blood urea nitrogen

ROS: 

Reactive oxygen species

Declarations

Acknowledgements

The authors thank all members of the laboratory for their useful comments and discussions.

Authors’ Contributions

KI (Isoda), YS, KI (Isama), and TN designed the study and wrote the Results and Discussion. YT and IT prepared samples. KI (Isoda), RN, and TH performed the experiments. KI (Isoda) and II wrote the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

Ethics Approval

The experimental protocols conformed to the ethical guidelines of the Teikyo Heisei University Graduate School of Pharmaceutical Sciences, compiled from the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Sciences.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Faculty of Pharmaceutical Sciences, Teikyo Heisei University

References

  1. Caputo A, Sparnacci K, Ensoli B, Tondelli L (2008) Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 5(4):230–42, Epub 2008/10/16. engView ArticleGoogle Scholar
  2. Dobson J (2006) Magnetic micro- and nano-particle-based targeting for drug and gene delivery. Nanomedicine (London, England) 1(1):31–7, Epub 2007/08/25. engView ArticleGoogle Scholar
  3. Nohynek GJ, Dufour EK, Roberts MS (2008) Nanotechnology, cosmetics and the skin: is there a health risk? Skin Pharmacol Physiol 21(3):136–49, Epub 2008/06/05. engView ArticleGoogle Scholar
  4. Nel A, Xia T, Madler L, Li N (2006) Toxic potential of materials at the nanolevel. Science 311(5761):622–7, Epub 2006/02/04. engView ArticleGoogle Scholar
  5. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW (2007) Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150(5):552–8, Pubmed Central PMCID: PMC2189773, Epub 2007/01/25. engView ArticleGoogle Scholar
  6. Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi X, Stauffer JL et al (2005) The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer. Oncogene 24(31):4873–82, Epub 2005/05/18. engView ArticleGoogle Scholar
  7. Matsuzaki H, Maeda M, Lee S, Nishimura Y, Kumagai-Takei N, Hayashi H et al (2012) Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol 2012:492608, Pubmed Central PMCID: PMC3304550, Epub 2012/04/14. engView ArticleGoogle Scholar
  8. Tsuda H, Xu J, Sakai Y, Futakuchi M, Fukamachi K (2009) Toxicology of engineered nanomaterials-a review of carcinogenic potential. APJCP 10(6):975–80, Epub 2009/01/01. engGoogle Scholar
  9. Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, Yagi K (2009) Silica nanoparticles as hepatotoxicants. Eur J Pharmaceut Biopharmaceut 72(3):496–501, Epub 2009/02/24. engView ArticleGoogle Scholar
  10. Shim KH, Jeong KH, Bae SO, Kang MO, Maeng EH, Choi CS et al (2014) Assessment of ZnO and SiO2 nanoparticle permeability through and toxicity to the blood-brain barrier using Evans blue and TEM. Int J Nanomed 9(Suppl 2):225–33, Pubmed Central PMCID: PMC4279764, Epub 2015/01/08. engGoogle Scholar
  11. Nohynek GJ, Dufour EK (2012) Nano-sized cosmetic formulations or solid nanoparticles in sunscreens: a risk to human health? Arch Toxicol 86(7):1063–75, Epub 2012/04/03. engView ArticleGoogle Scholar
  12. Watanabe S, Farias TM, Gennari RF, Ferraz GM, Kunzli R, Chubaci JF (2008) Chemical process to separate iron oxides particles in pottery sample for EPR dating. Spectrochim Acta A Mol Biomol Spectrosc 71(4):1261–5, Epub 2008/05/20. engView ArticleGoogle Scholar
  13. Schettler T (2006) Human exposure to phthalates via consumer products. Int J Androl 29(1):134–9, discussion 81-5. Epub 2006/02/10. engView ArticleGoogle Scholar
  14. Solhi L, Atai M, Nodehi A, Imani M (2012) A novel dentin bonding system containing poly(methacrylic acid) grafted nanoclay: synthesis, characterization and properties. Dental Mat 28(10):1041–50, Epub 2012/07/17. engView ArticleGoogle Scholar
  15. Karimi F, Taheri Qazvini N, Namivandi-Zangeneh R (2013) Fish gelatin/Laponite biohybrid elastic coacervates: a complexation kinetics-structure relationship study. Int J Biol Macromol 61:102–13, Epub 2013/07/09. engView ArticleGoogle Scholar
  16. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194–205, Epub 2008/02/23. engView ArticleGoogle Scholar
  17. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A et al (2009) Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci 13(3):197–200, Epub 2009/08/14. engGoogle Scholar
  18. Weber LW, Boll M, Stampfl A (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33(2):105–36, Epub 2003/04/24. engView ArticleGoogle Scholar
  19. Hartmann JT, Kanz L, Bokemeyer C (1999) Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 58(2):257–81, Epub 1999/09/03. engView ArticleGoogle Scholar
  20. Witjes JA (1997) Current recommendations for the management of bladder cancer. Drug therapy. Drugs 53(3):404–14, Epub 1997/03/01. engView ArticleGoogle Scholar
  21. Shimizu Y, Isoda K, Tezuka E, Yufu T, Nagai Y, Ishida I et al (2012) Influence of 50-nm polystyrene particles in inducing cytotoxicity in mice co-injected with carbon tetrachloride, cisplatin, or paraquat. Pharmazie 67(8):712–4, Epub 2012/09/11. engGoogle Scholar
  22. Isoda K, Tetsuka E, Shimizu Y, Saitoh K, Ishida I, Tezuka M (2013) Liver injury induced by thirty- and fifty-nanometer-diameter silica nanoparticles. Biol Pharmaceut Bull 36(3):370–5, Epub 2012/12/28. engView ArticleGoogle Scholar
  23. Yoshida T, Yoshioka Y, Tochigi S, Hirai T, Uji M, Ichihashi K et al (2013) Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Part Fibre Toxicol 10:41, Pubmed Central PMCID: PMC3751833, Epub 2013/08/21. engView ArticleGoogle Scholar
  24. Yu T, Hubbard D, Ray A, Ghandehari H (2012) In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release 163(1):46–54, Pubmed Central PMCID: PMC3476833, Epub 2012/06/12. engView ArticleGoogle Scholar
  25. Wu J, Danielsson A, Zern MA (1999) Toxicity of hepatotoxins: new insights into mechanisms and therapy. Expert Opin Invest Drugs 8(5):585–607, Epub 2005/07/05. engView ArticleGoogle Scholar
  26. Hassan I, Chibber S, Naseem I (2010) Ameliorative effect of riboflavin on the cisplatin induced nephrotoxicity and hepatotoxicity under photoillumination. Food Chem Toxicol 48(8-9):2052–8, Epub 2010/05/12. engView ArticleGoogle Scholar
  27. Maisanaba S, Pichardo S, Puerto M, Gutierrez-Praena D, Camean AM, Jos A (2015) Toxicological evaluation of clay minerals and derived nanocomposites: a review. Environ Res 138:233–54, Epub 2015/03/04. engView ArticleGoogle Scholar

Copyright

© The Author(s). 2017